Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (581-590 of 602) with videos related to

Pageof 61
Sort By:
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2025
Genomics Define Malignant Transformation in Myeloma Precursor ConditionsFrancesco Maura, P Leif Bergsagel, Bachisio Ziccheddu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Pageof 61

Showing results (581-590 of 602) with videos related to

Sort By:
Pageof 61
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2025
Genomics Define Malignant Transformation in Myeloma Precursor ConditionsFrancesco Maura, P Leif Bergsagel, Bachisio Ziccheddu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Pageof 61